Reach Us +1-504-608-2390
How The New Compouds Of Ruthenium Present Potencial Of Treatment Of The Cancer? | 5846
ISSN: 2161-0495

Journal of Clinical Toxicology
Open Access

Like us on:

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations
700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

How the new compouds of ruthenium present potencial of treatment of the cancer?

International Toxicology Summit & Expo

Elisangela de Paula Silveira Lacerda

AcceptedAbstracts: J Clinic Toxicol

DOI: 10.4172/2161-0495.S1.008

T he limitations of cisplatin-based chemotherapy, including high toxicity, undesirable side effects, and drug resistance, have motivated extensive investigations into alternative metal-based cancer therapies. A range of Ruthenium?s complexes has been synthesized and tested for antitumor properties. Ruthenium (II) complexes are increasingly attracting the interest of researchers due to their promising pharmacological properties and selectivity to cells tumor. The aim of this work was to study of the cytotoxic activity, arrest cell cycle and the mechanism of apoptosis of many cell lines induced by ruthenium compound Ruin vitro in many line cell tumor. The present study determined the effects of these compoundsinA549, K562, DU 145, S180, A20, B16F10 and Erlich tumor cellslines and the normal cells like L929, MRC5 and lymphocyte to study the citotoxicity activity, cell cycle distribution, induction apoptosis, mitochondrial membrane potential, caspase activity and mRNA expression of genes bax, caspase-3, 8 and 9. The MTT assay revealed that the IC50 for the compounds after 24 and 48 h of treatment incubation with the tumor line cells was approximately 0.2 to 31.15 μM. Cell cycle analysis revealed that some compounds of Ru(II)were capable of change cell cycle distribution since the percentage of cells in the G1 phases increased. In addition, treatment with these compounds induced apoptotic cell death in S180, A549, K562 and Erlich tumor cells, demonstrated by the increased numbers of Annexin V-positive cells, activation caspase 3 and 9 and marked decrease in mitochondrial membrane potential. Real time RT-PCR analysis revealed that Ru increased significant mRNA expression of many biomarket like bax and caspase-3, 8 and 9. In summary, the new compounds of Ruthenium displayed a significant effect cytotoxic through cell cycle arrest and apoptotic induction in many tumor line cells, which suggests these compounds might have therapeutic potential anticancer
Elisangela de Paula Silveira Lacerda has completed his Ph.D at the age of 25 years from Federal University of Uberlnadia in Genetics and Biochemistry. She is the professor of the Federal University of Goi?s and the president of the Society of Genetics Region Goias. She has published more than 20 papers in reputed journals and serving as an editorial board member of repute